The abstract is read at the publisher; the summary is JClub's.
In adult unipolar major depressive disorder, escitalopram, duloxetine, and agomelatine achieved higher sustained response than fluoxetine in long-term continuation/continuation-extension trials.
- Why it matters: Relapse and chronicity in major depressive disorder require treatments that maintain response over time, but comparative long-term evidence across antidepressants is incomplete.
- What they did: A systematic review and network meta-analysis of 115 double-blind randomized trials (n=30,428) compared 21 antidepressants head-to-head or versus placebo for >12 weeks, using random-effects pairwise and network odds ratios with fluoxetine as reference.
- The result: In 35 continuation/continuation-extension studies (n=9,888), escitalopram (OR 1·62, 95% CI 1·21–2·18), duloxetine (OR 1·57, 1·08–2·26), and agomelatine (OR 1·40, 1·06–1·85) had higher sustained response than fluoxetine, with escitalopram (OR 0·60, 0·43–0·83) and duloxetine (OR 0·64, 0·44–0·95) showing lower all-cause discontinuation; evidence certainty and risk of bias may limit reliability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.